Sight Sciences, Inc. (SGHT)

NMS – Цена в реальном времени. Валюта: USD

8.28

+0.53 (6.84%)

При закрытии: Aug 12, 2026, 4:00 PM EDT

8.28

0.00 (0.00%)

После закрытия: Aug 12, 2026, 4:10 PM EDT

06.08.2026

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

06.08.2026

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences NASDAQ: SGHT reported second-quarter revenue growth of 20% year over year, supported by gains in its interventional glaucoma and interventional dry eye businesses, while reducing operating expenses and cash usage. The company raised its full-year revenue outlook and lowered its adjusted operating expense guidance.

05.08.2026

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences, Inc. (SGHT) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.15. This compares to a loss of $0.23 per share a year ago.

05.08.2026

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

The headline numbers for Sight Sciences (SGHT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

05.08.2026

Sight Sciences Reports Second Quarter 2026 Financial Results

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance

04.08.2026

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation. New system expands the Company's leadership in interventional glaucoma with the first FDA cleared MIGS device for single pass canaloplasty with TruSync™ Plus innovation.

Видео

No Data

There is no data to display

Повышения / Понижения рейтинга

Тикер	Фирма	Изменение рейтинга	Целевая цена	Дата
SGHT	UBS	Buy	undefined >> $7	July 28th 2026

Пресс-релизы

05.08.2026

Sight Sciences Reports Second Quarter 2026 Financial Results

Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance Raises Full-Year 2026 Revenue Guidance and Reduces Adjusted Operating Expense Guidance

Sight Sciences, Inc. (SGHT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Sight Sciences, Inc. (SGHT)

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Search stocks

Sight Sciences, Inc. (SGHT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

Sight Sciences, Inc. (SGHT)

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences, Inc. (SGHT) Q2 2026 Earnings Call Transcript

Sight Sciences Q2 Earnings Call Highlights

Sight Sciences, Inc. (SGHT) Reports Q2 Loss, Tops Revenue Estimates

Sight Sciences (SGHT) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System

Видео

No Data

Повышения / Понижения рейтинга

Пресс-релизы

Sight Sciences Reports Second Quarter 2026 Financial Results

Sight Sciences Receives FDA 510(k) Clearance of the OMNI Ultra Surgical System